Palvella Therapeutics, Inc. Common Stock (PVLA) Stock Price

PVLAStock

$149.97+192.34%52W

Market Cap$2.16B

P/E—

PEG Ratio—

Div yield—

Beta-0.23

PVLA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)12.62%

Price vs S&P 500 (4W)4.99%

VGM Score41.63

Book Value / Share (Quarterly)$15.06

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.44%

Cash Flow / Share (Quarterly)$-2.54

Price vs S&P 500 (YTD)30.46%

Net Profit Margin (TTM)-39.71%

EPS (TTM)$-4.82

10-Day Avg Trading Volume0.20M

EPS Excl Extra (TTM)$-4.82

Revenue Growth (5Y)8.03%

EPS (Annual)$-7.62

ROI (Annual)-22.80%

Net Profit Margin (5Y Avg)-102.68%

Cash / Share (Quarterly)$17.41

ROA (Last FY)-19.27%

Revenue Growth TTM (YoY)-97.15%

EBITD / Share (TTM)$-4.58

ROE (5Y Avg)-89.63%

Operating Margin (TTM)-47.76%

Cash Flow / Share (Annual)$-2.02

P/B Ratio10.33x

P/B Ratio (Quarterly)10.11x

Net Income / Employee (Annual)$-586,200

Net Interest Coverage (TTM)-73.89x

ROA (TTM)-38.33%

EPS Incl Extra (Annual)$-7.62

Current Ratio (Annual)5.20x

Quick Ratio (Quarterly)21.01x

3-Month Avg Trading Volume0.24M

52-Week Price Return192.34%

Revenue / Employee (TTM)$46,600

P/S Ratio (Annual)52.33x

Asset Turnover (Annual)1.11x

52-Week High$161.38

Operating Margin (5Y Avg)-106.68%

EPS Excl Extra (Annual)$-7.62

26-Week Price Return24.55%

Quick Ratio (Annual)5.11x

13-Week Price Return29.44%

Total Debt / Equity (Annual)0.63x

Current Ratio (Quarterly)21.18x

Enterprise Value$2.07B

Revenue / Share Growth (5Y)-2.80%

Asset Turnover (TTM)0.76x

Revenue / Employee (Annual)$1,476,200

Pretax Margin (Annual)-57.33%

Cash / Share (Annual)$4.68

3-Month Return Std Dev83.38%

Net Income / Employee (TTM)$-2,127,400

ROE (Last FY)-27.15%

Net Interest Coverage (Annual)-15.00x

EPS Basic Excl Extra (Annual)$-7.62

P/FCF (TTM)14935.76x

Receivables Turnover (TTM)1.91x

Total Debt / Equity (Quarterly)0.10x

EPS Incl Extra (TTM)$-4.82

Receivables Turnover (Annual)13.42x

ROI (TTM)-41.72%

P/S Ratio (TTM)54.74x

Pretax Margin (5Y Avg)-102.56%

Revenue / Share (Annual)$38.02

Price vs S&P 500 (52W)173.78%

Year-to-Date Return43.28%

5-Day Price Return2.90%

EPS Normalized (Annual)$-7.62

ROA (5Y Avg)-36.56%

Net Profit Margin (Annual)-57.33%

Month-to-Date Return7.86%

EBITD / Share (Annual)$-6.28

Operating Margin (Annual)-69.51%

LT Debt / Equity (Annual)0.63x

ROI (5Y Avg)-88.76%

LT Debt / Equity (Quarterly)0.10x

EPS Basic Excl Extra (TTM)$-4.82

P/B Ratio (Annual)44.27x

Pretax Margin (TTM)-39.71%

Book Value / Share (Annual)$2.26

Price vs S&P 500 (13W)27.49%

Beta-0.23x

P/FCF (Annual)46.87x

Revenue / Share (TTM)$0.76

ROE (TTM)-47.84%

52-Week Low$49.81

vGradeF

gGradeD

mGradeA

vgmGradeC

PVLA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$1.15	-$1.52	-31.98%(-$0.37)
Q1 2026	May 7, 2026	-$0.93	-$1.20	-29.29%(-$0.27)
Q4 2025	Mar 31, 2026	-$0.91	-$1.08	-18.58%(-$0.17)
Q3 2025	Nov 10, 2025	-$0.85	-$1.03	-21.31%(-$0.18)
Q2 2025	Aug 14, 2025	-$0.77	-$0.86	-11.98%(-$0.09)

PVLA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.23

4.26

4.23

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
PVLAPalvella Therapeutics, Inc. Common Stock	F	D	A	$149.97
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Palvella Therapeutics, Inc. Common Stock

Palvella Therapeutics is a late-stage biopharmaceutical company developing treatments for rare genetic skin diseases that currently lack approved therapies. The company's lead candidate, QTORIN rapamycin gel, is based on its proprietary QTORIN platform and is in clinical development for two rare genetic skin disorders.